Although immune-inflammatory treatment is not routinely recommended to be used for SARS-CoV-2
pneumonia, according to the pathological findings of pulmonary oedema and hyaline membrane
formation, timely and appropriate use of immune modulator together with ventilator support
should be considered for the severe patients to prevent ARDS development. The
sphingosine-1-phosphate receptor regulators Fingolimod (FTY720) is an effective immunology
modulator which has been widely used in multiple sclerosis.The aim of this study was to
determine whether the efficacy of fingolimod for a novel coronavirus disease (COVID-19).
Phase:
Phase 2
Details
Lead Sponsor:
First Affiliated Hospital of Fujian Medical University